20/05/2015 : THERADIAG AND HOSPIRA SIGN A PARTNERSHIP AGREEMENT

Hospira to provide Theradiag’s LISA TRACKER infliximab monitoring kits jointly with biosimilar Inflectra® in Europe, Canada and Australia   Croissy-Beaubourg and Montpellier, May 20, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics…

Continue Reading 20/05/2015 : THERADIAG AND HOSPIRA SIGN A PARTNERSHIP AGREEMENT

11/05/2015 : THERADIAG LAUNCHES LISA TRACKER IN CANADA

Exclusive partnership agreement with Somagen Diagnostics Inc.First North American market penetration for LISA TRACKERPositive recommendation by Canadian health authorities on biotherapy monitoring Croissy-Beaubourg and Montpellier, May 11, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing…

Continue Reading 11/05/2015 : THERADIAG LAUNCHES LISA TRACKER IN CANADA

29/04/2015 : Monitoring of infliximab and C-Reactive Protein can predict loss of response in inflammatory bowel disease

A study conducted at the Saint-Etienne University Hospital sustains the relevance of infliximab monitoring with LISA TRACKER kits and dosing of C-Reactive Protein (CRP) to predict loss of response in IBD patientsMonitoring of biotherapies with…

Continue Reading 29/04/2015 : Monitoring of infliximab and C-Reactive Protein can predict loss of response in inflammatory bowel disease